Hao F, Wu DD, Xu X, Cui M. Histamine induces activation of protein kinase D that mediates tissue factor expression and activity in human aortic smooth muscle cells. Am J Physiol Heart Circ Physiol 303: H1344 -H1352, 2012. First published September 21, 2012; doi:10.1152/ajpheart.00500.2011.-Histamine, an inflammatory mediator, has been shown to influence the pathogenesis of vascular wall cells. However, the molecular basis of its influence is not well understood. Our data reveal that histamine markedly induces protein kinase D (PKD) activation in human aortic smooth muscle cells. PKD belongs to a family of serine/threonine protein kinases, and its function in vascular disease is largely unknown. Our data show that histamine-induced PKD phosphorylation is dependent on the activation of histamine receptor 1 and protein kinase C (PKC). To determine the role of PKD in the histamine pathway, we employed a smallinterfering RNA approach to downregulate PKD expression and found that PKD1 and PKD2 are key mediators for expression of tissue factor (TF), which is the key initiator of blood coagulation and is important for thrombosis. Our results show that PKD2 predominantly mediates histamine-induced TF expression via the p38 mitogenactivated protein kinase (MAPK) pathway, whereas PKD1 mediates histamine-induced TF expression through a p38 MAPK-independent pathway. We demonstrate that histamine induces TF expression via the PKC-dependent PKD activation. Our data provide the first evidence that PKD is a new component in histamine signaling in live cells and that PKD has a novel function in the histamine signaling pathway leading to gene expression, as evidenced by TF expression. Importantly, our data reveal a regulatory link from histamine to PKD and TF, providing new insights into the mechanisms of coagulation and the development of atherothrombosis. histamine receptor; protein kinase activation; phosphorylation; tissue factor; vascular wall cells HISTAMINE IS A SMALL MOLECULE amine that is mainly produced by histidine decarboxylase (HDC) from mast cells and monocyte-derived macrophages (18, 32) . HDC is found in macrophage-derived foam cells (10), and HDC knockout mice show reduced neointimal thickening (22), suggesting a role of histamine in the development of vascular disease.
HISTAMINE IS A SMALL MOLECULE amine that is mainly produced by histidine decarboxylase (HDC) from mast cells and monocyte-derived macrophages (18, 32) . HDC is found in macrophage-derived foam cells (10) , and HDC knockout mice show reduced neointimal thickening (22) , suggesting a role of histamine in the development of vascular disease.
As a potent inflammatory molecule, histamine increases blood vessel permeability and endothelial dysfunction (21, 26) and induces relaxation (15, 36) and constriction (13) of blood vessels. Through the cross talk between calcium flow and mitogen-activated protein kinase (MAPK) induction, histamine may be a risk factor for hypertension (5) . Histamine exerts its function through its four receptors (32) . We reported previously that histamine induces expression of the master transcription factor Egr-1 in human aortic endothelial cells (8) . Histamine also induces tissue factor (TF) expression in smooth muscle cells (SMCs) related to acute coronary syndrome (27) . In addition, histamine increases the expression of cytokines such as interleukin (IL)-6 and IL-8 (4, 11) . The antagonists of histamine receptor 1 (H 1 ) abolish the effect of histamine and reduce the formation of intimal hyperplasia (14) . Recently, it has been reported that histamine H 1 receptor promotes the development of atherosclerotic lesions by increasing vascular permeability for low-density lipoprotein (LDL) (19) .
Protein kinase D (PKD), a family of serine and threonine protein kinases, consists of PKD1, PKD2, and PKD3. PKDs have been implicated in various cellular functions (7, 9, 25) . However, the relationship between histamine and PKD in live cells and the functional role of PKD in the histamine pathway have not been revealed. Furthermore, although histamine activation of vascular SMCs is well documented, the activation cascade is still unclear. In the present study, we investigated the effect of histamine on activation of PKD in human aortic smooth muscle cells (HASMCs), PKD function in histamineregulated cellular events, and its implication in vascular diseases. Our results provide the first evidence that histamine activates PKD in living cells as evidenced by using HASMCs. Furthermore, the current study documents the functional role of PKD in histamine-induced cellular events. Importantly, our results reveal that histamine-activated PKD controls the expression of the key coagulation initiator TF and implies a new role for PKD in coagulation, atherothrombosis, and possibly other inflammatory diseases.
MATERIALS AND METHODS
Reagents. Histamine, mepyramine, and cimetidine were obtained from Sigma; pertussis toxin (PTX), SB-203580, and Ro-31-8220 were from Biomol International (Plymouth Meeting, PA). Antibodies against PKD1, PKD3, phospho (p)-PKD-activation loop (Ser 738/742 of human PKD1, Ser 706/710 of human PKD2, and Ser 731/735 of human PKD3), p-PKD1 COOH-termini (Ser 910 of human PKD1), p-extracellular signal-regulated kinase (ERK), p-p38 MAPK, and p-c-Jun NH 2-terminal kinase (JNK) were from Cell Signaling Technology (Beverly, MA). Antibody against p-PKD2 COOH-termini (Ser 876 , human) was from Millipore (Billerica, MA). Antibodies against PKD2 were from Bethyl Lab (Montgomery, TX). Antibody against ␤-actin was from Sigma-Aldrich (St. Louis, MO). Nonsilencing control small-interfering RNA (siRNA), PKD1 siRNA, PKD2 siRNA, and PKD3 siRNA were from Qiagen (Valencia, CA). The siRNA transfection reagent RNAi MAX was from Invitrogen. Antibodies against human TF antibody and ␣-actin as well as TF surface activity assay kit were from American Diagnostica (Stamford, CT). Goat antirabbit IgG Alexa Fluor 488 was from Invitrogen (Carlsbad, CA), and rhodamine red-X-conjugated goat anti-mouse IgG was from Jackson ImmunoResearch Laboratories (West Grove, PA).
Cell culture. HASMCs supplied by Cascade Biologics were cultured in Medium 231 with special SMGS supplements (Cascade Biologics). Cells were starved for 24 h before histamine stimulation. To detect histamine induction of TF protein expression, cells were stimulated with histamine for 5 h; to detect phosphorylation of PKDs and MAPKs, cells were stimulated for the indicated times as shown in Figs. 1-6 .
Western blot analysis. HASMCs were rinsed with cold PBS and lysed in lysis buffer (50 mM Tris·HCl, pH 6.8, 8 M urea, 5% mercaptoethanol, 2% SDS, protease inhibitors, and phosphatase inhibitors) with sonication for 20 s on ice. Cellular proteins were separated by 10% SDS-polyacrylamide gel electrophoresis and were transferred to a polyvinylidene fluoride membrane (Immobilon-P; Millipore). The membranes were then probed with the specific antibodies, and the specific protein bands were visualized by ECL-Plus (GE Healthcare).
siRNA transfection. Nonsilencing siRNA (20 nM), PKD1 siRNA (20 nM), PKD2 siRNA (20 nM), and PKD3 siRNA (20 nM) were transfected into HASMCs using the RNAi MAX transfection reagent according to the manufacturer's instructions (Invitrogen). Nonsilencing siRNA was used as a negative control. Forty-eight hours after transfection, the cells were starved for 24 h followed by treatment with or without histamine.
TF surface activity assay. Cell-surface TF activity was measured with the Actochrome TF activity assay kit purchased from American Diagnostica. Briefly, HASMCs were stimulated with histamine (10 M) for 5 h. The cells were washed two times with PBS. Assay buffer (300 l, pH 8.4), 25 l factor VIIa, and 25 l factor X were added to 12-well cell culture plates, and the plates were stirred on an orbital rotator for 15 min at 37°C. Next, 25 l Spectrozyme factor Xa substrate was added and incubated at 37°C for 20 min with constant stirring. Aliquots of the reaction mixture were pipetted into 96-well plates and read along with the standards provided by American Diagnostica on a Universal microplate reader Synergy HT (Bio-TEK Instruments) at 405 nm.
Immunofluorescence analysis. Cells grown in 12-well chamber cover glass slides were fixed in 4% paraformaldehyde solution for 30 min, permeabilized with 0.3% Triton X-100 in PBS for 5 min at room temperature, blocked with 5% goat serum (Sigma) plus 0.1% Tween 20 in PBS for 45 min, and then incubated with antibodies against p-PKD1 (Ser 910 ), p-PKD2 (Ser 876 ), or ␣-actin in 1:200 dilution overnight at 4°C. After being washed with PBS three times (5 min for each), the cells were incubated with the secondary antibody, goat anti-rabbit IgG Alexa Fluor 488, or rhodamine red-X-conjugated goat anti-mouse IgG for 2 h at room temperature and then washed with PBS three times at room temperature. Subsequently, the cover slips were mounted on slides with permanent aqueous mounting medium (Biogenex), and the labeled cells were analyzed by fluorescence microscopy with a Nikon Eclipse E600 microscope.
Data analysis. All data are representative of a minimum of three experiments. Results are expressed as means Ϯ SE. Comparisons between multiple groups were performed using one-way ANOVA with post hoc Dunnett's t-tests. A single comparison analysis was made using two-tailed, unpaired Student's t-tests. A P value of 0.05 was considered statistically significant.
RESULTS

All three PKD isoforms are expressed in HASMCs.
To investigate histamine's effect on the activation of PKD, we first examined the expression levels of PKD isoforms in HASMCs. The cell lysates of HASMCs were collected and examined by Western blotting with specific antibodies against three isoforms of PKD family members: PKD1, PKD2, and PKD3. Cell lysates of HEK293 were used as a positive control, as we reported previously that three isoforms of PKDs are expressed in these cells (31) . As shown in Fig. 1A , PKD1, PKD2, and PKD3 are all expressed in HASMCs.
Histamine rapidly and markedly induces activation of PKD in HASMCs.
The regulatory relationship between histamine and PKD is currently unknown. To determine whether histamine activates PKD in HASMCs, we examined PKD phosphorylation in HASMCs upon stimulation with histamine using a specific antibody that recognizes phosphorylated serine residues at the activation loop common to all three isoforms of PKD (for human PKD1, at Ser 738 and Ser 742 ; for human PKD2, at Ser 706 and Ser 710 ; and for human PKD3, at Ser 731 and Ser 735 ). Phosphorylation of these serine residues correlates to PKD catalytic activity (20) . Cultured HASMCs were starved for 24 h and then treated with 10 M histamine for various times. As shown in Fig. 1 , B and C, we observed that PKD activation (phosphorylation at the PKD activation loop) was markedly and rapidly induced with a peak at around 45 s to 2 min. It has been shown that phosphorylation of the serine residues at the COOH-terminus of PKD1 (Ser 910 for human and Ser 916 for mouse) occurs by autophosphorylation and correlates with the activation status of PKD1 (12, 34) ; similarly, it was found that the corresponding COOH-terminal serine in PKD2 (Ser 876 ) was also phosphorylated during activation of PKD2 and the degree of Ser 876 phosphorylation correlates to PKD2 catalytic activity (28) . However, PKD3 lacks a COOH-terminal phosphorylation site; therefore, its activation status cannot be examined at COOH-terminal phosphorylation. We found that histamine rapidly and strikingly induced the phosphorylation of PKD1 (Ser 910 ) and PKD2 (Ser 876 ) in HASMCs with a peak at around 2-5 min (Fig. 1, B and C). The histamine-induced phosphorylation of serine residues at COOH-termini of PKD1 and PKD2 as well as the PKD activation loop declined to baseline at around 30 -60 min ( Fig.  1 , B and C). As shown in Fig. 1 , D and E, histamine dosedependently induced phosphorylation of PKD1, PKD2, and the common PKD activation loop. These data indicate that histamine markedly induces activation of PKD1 and PKD2 in HASMCs. In the following studies, the histamine concentration of 10 M was chosen to stimulate HASMCs because it maximally induces PKD activation (Fig. 1C ) and because this dose is in the range found in neointimal lesions (6) .
Activated PKD is located in plasma membranes of HASMCs. To examine the location of histamine-induced phosphorylated PKD in HASMCs, we used an immunofluorescence technique with antibodies against phosphorylation sites of PKDs and found that histamine-induced phosphorylated PKD1 and PKD2 accumulated in the plasma membranes of HASMC as shown in Fig. 1, F and G.
Histamine-induced activation of PKD is mediated by the H 1 receptor but not histamine receptor 2. Histamine exerts its proinflammatory function through four receptors. H 1 and histamine receptor 2 (H 2 ) are expressed in vascular smooth muscle cells (24, 30, 32) . To determine which histamine receptor mediates histamine-induced PKD phosphorylation, we used the specific H 1 receptor antagonist mepyramine and the H 2 receptor antagonist cimetidine to pretreat HASMCs for 40 min; then the cells were treated with 10 M histamine for 5 min, and the phosphorylation of PKD1 and PKD2 was examined by Western blotting. As shown in Fig. 2, A and B, pretreatment with the H 1 receptor antagonist mepyramine dosedependently blocked phosphorylation of PKD1 and PKD2; however, pretreatment with the H 2 receptor antagonist cimetidine had no effect on the activation of PKD1 and PKD2 (Fig. 2, C and D) .
These results indicate that histamine-induced activation of PKD is mediated by the H 1 receptor, but not the H 2 receptor, in HASMCs.
Histamine-induced PKD phosphorylation is independent of G i/o proteins. Various G proteins are coupled with histamine receptors to mediate histamine-induced intracellular signaling. To determine whether G i/o proteins mediate histamine-induced phosphorylation of PKD1 and PKD2, we pretreated HASMCs with PTX (100 ng/ml), a specific inhibitor of G i/o proteins. Next, cells were treated with histamine (10 M) for 5 min followed by the detection of PKD phosphorylation. As shown in Fig. 3, A and B, treatment with PTX had no effect on the phosphorylation of PKD1 and PKD2 induced by histamine, suggesting that histamine-induced PKD activation in HASMCs is independent of G i/o protein mediation.
Protein kinase C mediates histamine-induced PKD phosphorylation. Both protein kinase C (PKC)-dependent and -independent activation of PKD in mammalian cells have been reported (1) (2) (3) . To assess whether histamine-induced PKD activation is mediated by PKC, we pretreated HASMCs with various concentrations of the PKC inhibitor Ro-31-8220 for 40 min and then stimulated cells with 10 M histamine for 5 min. As shown in Fig. 3 , C and D, we found that the PKC inhibitor Ro-31-8220 dose-dependently blocked histamine-induced PKD phosphorylation. Ro-31-8220 at 2 M nearly completely eliminated the phosphorylation of PKDs. These results indicated that histamine-induced PKD activation is mediated by PKC in HASMCs.
PKD2 mediates histamine-induced phosphorylation of p38 MAPK but does not affect phosphorylation of ERK and JNK MAPKs. The role of PKD in the histamine signaling pathway has not been revealed. To begin to probe the role of PKD, we evaluated PKD's effect on MAPK activation, since histamine has been reported to activate MAPKs (27) . We examined whether knockdown of PKD expression, using specific siRNA , and ␣-actin were used, followed by a secondary antibody: goat anti-rabbit IgG Alexa Fluor 488 or rhodamine red-X-conjugated goat anti-mouse IgG. of PKD1, PKD2, or PKD3, has an effect on phosphorylation of MAPKs. The specific PKD siRNAs were transfected into HASMCs for 48 h followed by serum starvation for 24 h; then cells were stimulated with histamine (10 M) for 5 min. As shown in Fig. 4A , transfection of PKD1 siRNA completely depleted endogenous protein expression of PKD1, eliminated phosphorylation of PKD1, but had no effect on phosphorylation of ERK, JNK, and p38 MAPK. However, transfection of PKD2 siRNA, which completely depleted endogenous PKD2 protein expression and PKD2 phosphorylation, markedly inhibited phosphorylation of p38 MAPK. In contrast, PKD2 siRNA had no effect on phosphorylation of ERK and JNK induced by histamine. We also noticed that transfection of PKD3 siRNA completely eliminated endogenous protein expression of PKD3 but had no effect on phosphorylation of PKD1, PKD2, and MAPKs. These results indicate that PKD2, but not PKD1 or PKD3, is required for p38 MAPK activation in response to histamine stimulation.
MAPKs (p38, ERK, and JNK) do not have effects on PKD activation.
To evaluate whether histamine-activated MAPKs have a feedback role on PKD activation, we examined whether the treatment of HASMCs with specific MAPK inhibitors has an effect on PKD phosphorylation. As shown in Fig. 4B , treatment with the MEK-specific inhibitor U-0126, the JNKspecific inhibitor SP-600125, or the p38 MAPK-specific inhibitor SB-203580 had no effect on phosphorylation of PKD1 or PKD2. These results indicate that ERK, JNK, and p38 MAPK are not the upstream mediators of PKD and do not have a feedback effect on PKD activation in the histamine-signaling pathway.
PKD controls histamine-induced TF expression and activity in HASMCs. The above results reveal a novel role of PKD in the histamine signaling pathway. We demonstrated that PKD2 is responsible for histamine-induced phosphorylation of p38 MAPK. To explore the biological function of PKD in the histamine-induced cellular response, we examined whether PKD affects the coagulation pathway, an important pathway contributing to blood coagulation and thrombosis. Previously, it was reported that histamine induces TF expression via a MAPK pathway (27) . Interestingly, our results demonstrated that PKD2 mediates histamine-induced p38 MAPK activation (Fig. 4A) . Therefore, we examined the role of PKD in histamine-induced TF expression and TF activity.
Interestingly, we observed that knockdown of the expression of PKD2 with PKD2 siRNA resulted in completely blocking histamine-induced TF protein expression (Fig. 5A) , whereas knockdown of PKD1 expression also resulted in remarkable inhibition of TF expression. However, depletion of PKD3 expression with siRNA had no effect on TF expression. We also examined the effect of knockdown of the specific PKD isoform on TF activity. We found that knockdown of the expression of PKD2 with PKD2 siRNA resulted in completely blocking histamine-induced TF surface activity (Fig. 5B) , whereas knockdown of PKD1 expression resulted in about 50% inhibition of TF activity. However, knockdown of PKD3 with PKD3 siRNA had no effect on the surface activity of TF in HASMCs (Fig. 5B) . Collectively, these data (Fig. 5) plus the results shown in Fig. 4A , where knockdown of PKD2 blocks p38 phosphorylation, support a conclusion that PKD2 predominantly mediates histamine-induced TF expression and activity via the p38 pathway, and, while the role of PKD1 is mild compared with PKD2, PKD1 also mediates TF expression and activity via a p38-independent pathway. In contrast, PKD3 has no effect on histamine-induced TF expression.
PKC, an upstream kinase of PKD, mediates p38 MAPK activity and TF expression. As shown in Fig. 3, C and D , phosphorylation of PKDs is mediated by PKC. Moreover, data shown in Fig. 4A indicate that PKD2 mediates phosphorylation of p38 MAPK. We next determined whether PKC mediates histamine-induced phosphorylation of p38 MAPK. As shown in Fig. 6A , the PKC-specific inhibitor Ro-31-8220 at 2 M markedly inhibited histamine-induced p38 MAPK phosphorylation, indicating that PKC, via the PKD2 pathway, mediates p38 MAPK activation in vascular SMCs.
To determine the effect of PKC, the upstream mediator of PKD, on histamine-induced TF expression, we examined whether pretreatment of HASMCs with the PKC-specific inhibitor Ro-31-8220 affects histamine-induced TF protein expression compared with the effect of the p38 MAPK-specific inhibitor SB-203580, which was shown to inhibit histamineinduced TF expression (27) . As shown in Fig. 6B , pretreatment with the PKC-specific inhibitor Ro-31-8220 largely inhibited histamine-induced TF expression. Pretreatment with SB-203580 (10 M), as expected, also largely blocked histamine-induced TF expression. These results indicate that PKC-dependent, PKD2-mediated p38 MAPK activation is required for histamine-induced TF expression.
DISCUSSION
Recent evidence supports histamine's role in vascular diseases. In particular, histamine has been reported to stimulate vascular wall permeability and endothelial dysfunction (21, 26) . Histamine also induces expression and secretion of various cytokines and chemokines (4, 11) . Furthermore, histamine increases the formation of intimal hyperplasia (14, 19) , and histamine H 1 receptor promotes atherosclerotic lesion formation. Experimental data also show that knockout of the histamine-producing enzyme HDC reduces neointimal thickening (22) . These findings suggest that histamine directly and markedly promotes atherogenesis. Vascular SMCs are the major constituents of blood vessel media, and histamine activation of SMCs has been implicated in the development of atherosclerosis (23) . Therefore, understanding the histamine-induced intracellular signaling cascade of vascular SMC activation and identifying the role of the new components in the histamine signaling pathway are important to understanding the development of various vascular complications.
In the present study, our results demonstrate that histamine rapidly and markedly induces PKD activation in HASMCs. PKD activation is the early signaling event triggered by histamine, leading to histamine-initiated HASMC activation. Our data provide the first evidence, to the best of our knowledge, that inflammatory factor histamine activates the PKD pathway in live cells. PKDs have been reported to contribute to survival, proliferation, and migration of vascular SMCs and endothelial cells in response to growth factors (7, 9) . PKDs are also implicated in cardiac remodeling and could be a therapeutic target in heart failure (16). Our previous study reveals that PKD mediates human blood monocyte migration in a lysophosphatidylcholine-triggered pathway (31) . Therefore, the present finding that histamine activates PKD1 and PKD2 in HASMCs strongly suggests that PKD1 and PKD2 mediate the histamine signal, leading to vascular pathologies. Our results demonstrated that the H 1 , but not H 2 , receptor mediates histamine-induced activation of PKD1 and PKD2 in HASMCs, indicating a crucial role of H 1 receptor in histamineinduced cell events. In line with our findings, it has been reported that histamine increases TF expression (27) , induces Egr-1 expression (8), and promotes inducible nitric oxide synthase expression (33) through the activation of the H 1 receptor. Furthermore, the H 1 receptor promotes the development of atherosclerotic lesions by increasing vascular permeability for LDL (19) , and histamine H 1 receptor antagonists abolish the effect of histamine and reduce the formation of intimal hyperplasia (14) .
PKD activation is mediated by various G proteins, which couple to a variety of stimuli receptors. For instance, lysophosphatidic acid-induced PKD activation is mediated by G i proteins in Swiss 3T3 and Rat-1 cells (17) and by cooperation of G i , G q , and G 12/13 in a murine embryonic cell line (35) . The present study demonstrates that histamine-induced PKD activation is independent of G i/o protein mediation in HASMCs, in agreement with our previous report that histamine activation of endothelial cells is mediated by non-G i/o proteins (8) . It has been reported that both PKC-dependent and -independent activation of PKDs exist (1) (2) (3) . The present results show that PKC is required for histamine-induced PKD activation.
In searching for the downstream target of PKD in the histamine signaling pathway, we identified the specific effect of PKD isoforms on MAPK activation in HASMCs. Our data reveal the previously unknown regulatory relationship between PKD and MAPK (ERK, JNK, and p38 MAPK) in SMCs: that is, PKD2, but not PKD1, is required for p38 MAPK activation. We also evaluated the possible feedback of MAPK in mediating PKD activation, since it was previously shown that MAPK regulates PKD activation (29) . However, our data indicate that, in the histamine-triggered signaling pathway in SMCs, MAPK is downstream of PKD and does not have a significant feedback effect on PKD activation.
Importantly, the present study not only reveals the new signaling molecule PKD in the histamine-triggered signaling pathway and PKD2-p38 MAPK regulatory relationship, but also identifies the functional role of PKD in the histamine pathway and in the coagulation pathway. Our results indicate that PKD is required for TF expression and activity. TF, the key initiator of blood coagulation, plays an important role in thrombosis. We identified two possible pathways of how PKD contributes to TF expression: 1) the main pathway, PKD2 via p38 MAPK, regulates histamine-induced TF expression and TF cell surface activation, and 2) the minor pathway, PKD1 via a p38 MAPK-independent pathway, mediates TF expression and activation.
In summary, the present study reveals that PKD is a novel signaling component in the histamine pathway in live cells as evidenced by histamine activation of both PKD1 and PKD2 in HASMCs. Our data demonstrate that histamine-induced PKD activation is via the H 1 receptor, independent of G i/o proteins, and is mediated by PKC. More interestingly, the present study reveals a previously unknown role of PKD in the coagulation pathway: PKD is required for histamine-induced TF expression and TF cell surface activity. In line with growing evidence that histamine/histamine receptors are potent inflammatory factors, which worsen vascular lesions, our data suggest that PKD via its upregulation of TF may contribute to blood coagulation and atherothrombosis. Therefore, PKD may be a new and valuable therapeutic target for the treatment of coagulation and atherothrombosis.
